DEA Extends Telehealth Flexibilities for Six MonthsNHPCO The Drug Enforcement Agency (DEA) has extended “the COVID-19 telemedicine prescribing flexibilities for six months, from May 12, 2023 through November 11, 2023.” The following requirements must be met for the flexibilities to continue:
On March 1, 2023, a proposed rule was published in the Federal Register focused on telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation. This proposed rule applies only in limited circumstances when the prescribing practitioner wishes to prescribe controlled medications via the practice of telemedicine and has not otherwise conducted an in-person medical evaluation prior to the issuance of the prescription. NHPCO submitted comments and will provide additional updates as they are finalized. |